DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for paralytic strabismus — screening already-approved drugs against its 36-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleParalytic strabismus maps to a 36-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for paralytic strabismus is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
phosphatase and actin regulator 1 (PHACTR1) — PHACTR1 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet 16pdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 6ZEE · 1.9 Å · ligand 3,6,9,12,15,18-HEXAOXAICOSANE (16P). Experimental structure, not a prediction.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Fortschritte der Neurologie · Psychiatrie · 1986 · 3 citations
Dynamik der Augenbewegungen beim Lähmungsschielen
AbstractThe characteristic clinical signs of paralytic strabismus can be confounded by phenomena concerning either the ipsilateral and/or the contralateral eye, the latter particularly occurring when fixating with the paretic eye. Specific clinical and EOG-phenomena and the underlying dynamic mechanisms of the peripheral oculomotor apparatus in acute and chronic paralytic strabismus are described.
British Journal of Ophthalmology · 1984 · 3 citations · open access
Paralytic strabismus correction by adjustable suture technique.
AbstractThe surgical correction of four cases of paralytic strabismus, in which the muscle is repositioned postoperatively with the active co-operation of the patient, is described. The method adopted by the author, by inserting the suture near the limbus, increases the degree of adjustability and allows for more extensive repositioning of the conjunctiva.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
